Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
13
USNA Quote, Financials, Valuation and Earnings
Last price:
$18.99
Seasonality move
:
18.95%
Day range:
$20.22 - $21.17
52-week range:
$18.48 - $38.32
Dividend yield:
0%
P/E ratio:
23.21x
P/S ratio:
0.42x
P/B ratio:
0.72x
Volume:
104.5K
Avg. volume:
113.6K
1-year change:
-34.81%
Market cap:
$377.7M
Revenue:
$854.5M
EPS (TTM):
$0.89
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, USANA Health Sciences, Inc. has 88.77% upside to fair value with a price target of $39.00 per share.
USNA vs. S&P 500
-
Over the past 5 trading days, USANA Health Sciences, Inc. has underperformed the S&P 500 by -2.7% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
USANA Health Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
USANA Health Sciences, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter USANA Health Sciences, Inc. reported revenues of $213.7M.
Earnings Growth
-
USANA Health Sciences, Inc. earnings have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter USANA Health Sciences, Inc. reported earnings per share of -$0.36.
Enterprise value:
285.8M
EV / Invested capital:
--
Price / LTM sales:
0.42x
EV / EBIT:
6.83x
EV / Revenue:
0.31x
PEG ratio (5yr expected):
--
EV / Free cash flow:
15.29x
Price / Operating cash flow:
20.73x
Enterprise value / EBITDA:
3.71x
Gross Profit (TTM):
$694.7M
Return On Assets:
2.42%
Net Income Margin (TTM):
1.92%
Return On Equity:
3.06%
Return On Invested Capital:
2.99%
Operating Margin:
0.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $927.9M | $862M | $912.7M | $200.2M | $213.7M | |
| Gross Profit | $734M | $683.5M | $694.7M | $157.4M | $156.9M | |
| Operating Income | $91.4M | $82.3M | $41.8M | $15.6M | $1.2M | |
| EBITDA | $112.2M | $103.5M | $77.1M | $21.2M | $10.8M | |
| Diluted EPS | $3.09 | $2.83 | $0.89 | $0.56 | -$0.36 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $368.4M | $341.2M | $390.5M | $451.2M | $264.1M | |
| Total Assets | $578.9M | $556.1M | $601.1M | $671.3M | $726.6M | |
| Current Liabilities | $158M | $125.8M | $112.6M | $114.8M | $118.7M | |
| Total Liabilities | $179.9M | $145M | $130.8M | $138.2M | $145M | |
| Total Equity | $399.1M | $411.1M | $470.4M | $533.1M | $581.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $85.1M | $81.2M | $31.5M | $29.5M | -$2M | |
| Cash From Investing | -$7.9M | -$15.3M | -$216.4M | -$2.3M | -$3.2M | |
| Cash From Financing | -$15M | -$12.7M | -$31.1M | -$78K | -$979K | |
| Free Cash Flow | $74.6M | $65.6M | $18.7M | $27.1M | -$5.2M | |
USNA
Sector
Market Cap
$377.7M
$100.9M
Price % of 52-Week High
53.91%
75.14%
Dividend Yield
0%
0%
Shareholder Yield
5.46%
2.38%
1-Year Price Total Return
-34.81%
-1.59%
Beta (5-Year)
0.671
0.246
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$21.06
200-day SMA
Sell
Level
$25.87
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$21.49
Relative Strength Index (RSI14)
Sell
Level
44.82
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-77.4936
50-day SMA
Buy
Level
$20.65
MACD (12, 26)
Buy
Level
5.49
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2905)
Buy
CA Score
(Annual)
Level (1.761)
Buy
Beneish M-Score
(Annual)
Level (-2.7578)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-2.1466)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm's brands include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.
Stock Forecast FAQ
In the current month, USNA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The USNA average analyst price target in the past 3 months is $39.00.
-
Where Will USANA Health Sciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that USANA Health Sciences, Inc. share price will rise to $39.00 per share over the next 12 months.
-
What Do Analysts Say About USANA Health Sciences, Inc.?
Analysts are divided on their view about USANA Health Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that USANA Health Sciences, Inc. is a Sell and believe this share price will drop from its current level to $39.00.
-
What Is USANA Health Sciences, Inc.'s Price Target?
The price target for USANA Health Sciences, Inc. over the next 1-year time period is forecast to be $39.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is USNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for USANA Health Sciences, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of USNA?
You can purchase shares of USANA Health Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase USANA Health Sciences, Inc. shares.
-
What Is The USANA Health Sciences, Inc. Share Price Today?
USANA Health Sciences, Inc. was last trading at $18.99 per share. This represents the most recent stock quote for USANA Health Sciences, Inc.. Yesterday, USANA Health Sciences, Inc. closed at $20.66 per share.
-
How To Buy USANA Health Sciences, Inc. Stock Online?
In order to purchase USANA Health Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get USNA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
USNA
Sector
P/E ratio
23.21x
17.34x
PEG ratio
--
0.12x
P/B ratio
0.72x
1.51x
Price / LTM sales
0.42x
0.51x
Growth Metrics
USNA
Sector
Revenue growth
6.72%
2.59%
Earnings growth
-164.14%
1.74%
Revenue (5-year growth)
-4.24%
3.41%
Earnings forecast
$0.41
$0.25
Profitability
USNA
Sector
Profitability FY 2024
$678.8M
$250.7M
Return on invested capital
2.99%
4.37%
Return on assets
2.42%
3.04%
Return on equity
3.06%
7.77%
Earnings Date
Last Earnings Date
Feb
17
Next Earnings Date
Feb
19
Estimated Next Earnings Date
May
21
Balance Sheet
USNA
Sector
Total cash
$145.3M
$85.8M
Short term investments
--
$31.1M
Total assets
$748.2M
$1.1B
Long term debt
--
$5.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
60
HYMC alert for Feb 18
Hycroft Mining Holding Corp. [HYMC] is up 21.1% over the past day.
Buy
67
ACLS alert for Feb 18
Axcelis Technologies, Inc. [ACLS] is down 16.57% over the past day.
Sell
40
GPN alert for Feb 18
Global Payments, Inc. [GPN] is up 16.5% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
